首页 | 本学科首页   官方微博 | 高级检索  
     

康柏西普治疗渗出性年龄相关性黄斑变性的临床观察
引用本文:李昆,彭娟,高丹宇. 康柏西普治疗渗出性年龄相关性黄斑变性的临床观察[J]. 国际眼科杂志, 2017, 17(12): 2342-2344. DOI: 10.3980/j.issn.1672-5123.2017.12.39
作者姓名:李昆  彭娟  高丹宇
作者单位:1. 中国人民解放军第451医院眼科, 中国陕西省西安市,710062;2. 国际眼科杂志编辑部, 中国陕西省西安市,710054
摘    要:目的:分析康柏西普治疗渗出性年龄相关性黄斑变性(age-related macular degeneration,ARMD)的临床疗效.方法:选择2016-01/2017-01我院眼科收治的渗出性ARMD患者21例21眼为研究对象,所有患者均行玻璃体腔内注射康柏西普0.05mL(0.5mg).术后随访3mo,观察术前、术后1wk,1、3mo最佳矫正视力(best corrected visual acuity,BCVA)和黄斑中心凹视网膜厚度(central macular thickness,CMT)的变化.结果:术前和术后1wk,1、3mo患者BCVA分别为0.9±1.4、0.7±1.2、0.5±1.1、0.4±0.9.手术前后患者BCVA具有时间差异性(F=49.12,P<0.001).术后1wk,1mo分别与术前比较差异均无统计学意义(P>0.05);术后3 mo与术前比较,差异有统计学意义(P<0.05).术后3mo,视力改善19眼,视力不变2眼.术前、术后1wk,1、3 mo患者CMT分别为404.25±68.76、354.25±43.12、271.75±32.30、218.30±24.70μm.手术前后患者CMT具有时间差异性(F=2487.45,P<0.001).术后1wk,1、3 mo分别与术前比较,差异均有统计学意义(P<0.001).未发现与药物有关的全身不良反应及眼部并发症.结论:玻璃体腔内注射康柏西普治疗渗出性ARMD疗效显著.

关 键 词:渗出性年龄相关性黄斑变性  康柏西普
收稿时间:2017-07-31
修稿时间:2017-10-23

Analysis on Conbercept for exudative age-related macular degeneration
Kun Li,Juan Peng and Dan-Yu Gao. Analysis on Conbercept for exudative age-related macular degeneration[J]. International Eye Science, 2017, 17(12): 2342-2344. DOI: 10.3980/j.issn.1672-5123.2017.12.39
Authors:Kun Li  Juan Peng  Dan-Yu Gao
Affiliation:Department of Ophthalmology, No.451 Hospital of Chinese PLA, Xi''an 710062, Shaanxi Province, China,Editorial Office, International Eye Science, Xi''an 710054, Shaanxi Province, China and Department of Ophthalmology, No.451 Hospital of Chinese PLA, Xi''an 710062, Shaanxi Province, China
Abstract:·AIM:To analyze the effect of Conbercept for exudative age-related macular degeneration ( ARMD) .·METHODS: There were 21 eye of 21 patients with exudative ARMD from January 2016 to January 2017 included. All the patients were treated with intravitreal injection of conbercept 0. 5mL (0. 5mg) and followed up for 3mo. The best corrected visual acuity ( BCVA) and central macular thickness (CMT) before and 1wk, 1 and 3mo after treatment were observed.·RESULTS:The BCVA and CMT before and 1wk, 1 and 3mo after treatment were 0. 9±1. 4, 0. 7±1. 2, 0. 5±1. 1 and 0. 4±0. 9. BCVA after treatment were different at different time (F=49. 12, P<0. 001); BCVA at 1wk and 1mo after treatment were not different compared with before treatment ( P> 0. 05 ); that at 3mo were significantly different compared with before (P<0. 05). There were 19 eyes with improved BCVA at 3mo after treatment, unchanged in 2 eyes. CMT before and at 1wk, 1 and 3mo were 404. 25±68. 76, 354. 25±43. 12, 271. 75±32. 30, 218. 30± 24. 70μm. CMT at different time were significantly different (F=2487. 45, P<0. 001);CMT at 1wk, 1 and 3mo were different compared with before treatment ( P <0. 001). There were no severe complications found.·CONCLUSION: Intravitreal injection of conbercept for exudative ARMD is remarkable.
Keywords:exudative age-related macular degeneration   conbercept
本文献已被 万方数据 等数据库收录!
点击此处可从《国际眼科杂志》浏览原始摘要信息
点击此处可从《国际眼科杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号